ENGN enGene Therapeutics (ENGN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001980845
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
40
13F, latest reported quarter
What the filings say about ENGN
Insiders, 180 days
+$10.1K net bought
1 buyer
enGene Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, enGene Therapeutics Inc. insiders bought a net $10.1K of stock across 19 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 5,102 shares held after it.
- No other insider bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim Chief Medical Officer Grossman William bought about $10.1K of ENGN on Sep 22, 2026, the largest insider purchase at the company since 2024; 40 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 18.5% of the 3,032,430 shares held after it.
- 1 other insider bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Forbion Growth Management B.V. bought about $5.0M of ENGN on Oct 30, 2024, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 40 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Oct 7, 2024.
- +7.6% median (+37.9% mean) 90-day return after 10 previous buys.
- The trade is 0.0% of the 2,470,633 shares held after it.
- 2 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Forbion Growth Opportunities Fund I Cooperatief U.A. bought about $5.3K of ENGN on Oct 8, 2024; 2 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Oct 4, 2024.
- +6.5% median (+40.8% mean) 90-day return after 9 previous buys.
- The trade is 0.5% of the 2,469,833 shares held after it.
- 2 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Forbion Growth Opportunities Fund I Cooperatief U.A. bought about $77.6K of ENGN on Oct 7, 2024; 2 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Oct 3, 2024.
- +6.2% median (+45.1% mean) 90-day return after 8 previous buys.
- The trade is 0.2% of the 2,457,989 shares held after it.
- 2 other insiders bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Forbion Growth Opportunities Fund I Cooperatief U.A. bought about $39.2K of ENGN on Oct 4, 2024; 2 other insiders bought within 30 days and 40 funds added in the latest 13F quarter.19 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$10.1K over 180 days
+$10.1K over 90 days
more than 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
40 funds bought in last quarter
below 57% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.3% of the float short (float per yahoo 2026-10-26) · 1.8 days to cover · settled 2026-09-30
below 66% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ENGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-79.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ENGN: institutional holders (13F)
13F holdings, latest reported quarter
12,510,709 sh
$17.5M
6,669,908 sh
$11.5M
6,256,662 sh
$10.8M
4,822,169 sh
$8.3M
2,675,876 sh
$4.6M
Congress trades in ENGN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ENGN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ENGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
NORTH SQUARE KENNEDY MICROCAP FUND
$14.2K position · as of 2026-05-31
0.0%
JNL/DFA U.S. Small Cap Fund
$17.3K position · as of 2026-06-30
0.0%
TIFF MULTI-ASSET FUND
$18.4K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$75.4K position · as of 2026-05-31
0.0%
AST Small-Cap Equity Portfolio
$2.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $10.1K bought by insiders over 180 days, 40 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ENGN financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ENGN
| FY Oct 2025 | n/a |
| FY Oct 2024 | n/a |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ENGN
| FY Oct 2025 | n/a |
| FY Oct 2024 | n/a |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$104.0M
operating cash flow minus capex, 2025-08-01 to 2026-07-31
Free cash flow, TTM ENGN
| FY Oct 2025 | -$100.7M |
| FY Oct 2024 | -$49.2M |
| FY Oct 2023 | -$25.1M |
| FY Oct 2022 | n/a |
| Jul 2026 | -$18.9M |
| Apr 2026 | -$30.6M |
| Jan 2026 | -$29.1M |
| Oct 2025 | -$25.4M |
| Jul 2025 | -$26.3M |
| Apr 2025 | -$23.0M |
| Jan 2025 | -$26.0M |
| Oct 2024 | -$19.8M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2024-10-31 (21 months older than the period end); equity 2026-07-31
Debt to equity ENGN
| FY Oct 2025 | 0.00x |
| FY Oct 2024 | 0.00x |
| FY Oct 2023 | 0.00x |
| FY Oct 2022 | n/a |
| Jul 2026 | 0.00x |
| Apr 2026 | 0.00x |
| Jan 2026 | 0.00x |
| Oct 2025 | 0.00x |
| Jul 2025 | 0.00x |
| Apr 2025 | 0.00x |
| Jan 2025 | 0.00x |
| Oct 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt ENGN
| FY Oct 2025 | n/a |
| FY Oct 2024 | n/a |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-60.5%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on equity ENGN
| FY Oct 2025 | -53.3% |
| FY Oct 2024 | -32.0% |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | -60.5% |
| Apr 2026 | -52.6% |
| Jan 2026 | -46.1% |
| Oct 2025 | -53.3% |
| Jul 2025 | -44.0% |
| Apr 2025 | -34.0% |
| Jan 2025 | -44.2% |
| Oct 2024 | -32.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-48.8%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on assets ENGN
| FY Oct 2025 | -44.0% |
| FY Oct 2024 | -27.7% |
| FY Oct 2023 | -180.2% |
| FY Oct 2022 | n/a |
| Jul 2026 | -48.8% |
| Apr 2026 | -44.2% |
| Jan 2026 | -39.3% |
| Oct 2025 | -44.0% |
| Jul 2025 | -37.0% |
| Apr 2025 | -29.6% |
| Jan 2025 | -36.4% |
| Oct 2024 | -27.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ENGN
| FY Oct 2025 | n/a |
| FY Oct 2024 | n/a |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-56.2%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
Return on capital employed ENGN
| FY Oct 2025 | -50.7% |
| FY Oct 2024 | -32.9% |
| FY Oct 2023 | -51.9% |
| FY Oct 2022 | n/a |
| Jul 2026 | -56.2% |
| Apr 2026 | -49.6% |
| Jan 2026 | -43.6% |
| Oct 2025 | -50.7% |
| Jul 2025 | -42.3% |
| Apr 2025 | -34.1% |
| Jan 2025 | -43.5% |
| Oct 2024 | -32.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.47x
close 2026-10-26 over four quarters of diluted EPS, 2025-08-01 to 2026-07-31
P/E, trailing ENGN
| FY Oct 2025 | 2.22x |
| FY Oct 2024 | 5.90x |
| FY Oct 2023 | 0.14x |
| FY Oct 2022 | n/a |
| Jul 2026 | 0.53x |
| Apr 2026 | 2.21x |
| Jan 2026 | 2.97x |
| Oct 2025 | 2.22x |
| Jul 2025 | n/a |
| Apr 2025 | 6.57x |
| Jan 2025 | 4.41x |
| Oct 2024 | 5.90x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$64.9M
market value at close 2026-10-26 on 2026-09-02 shares, plus long-term debt only, 2024-10-31 (21 months older than the period end), minus cash 2026-07-31
Enterprise value ENGN
| FY Oct 2025 | $318.9M |
| FY Oct 2024 | $218.3M |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | $78.9M |
| Apr 2026 | $457.2M |
| Jan 2026 | $601.8M |
| Oct 2025 | $318.9M |
| Jul 2025 | $161.1M |
| Apr 2025 | $153.5M |
| Jan 2025 | $279.2M |
| Oct 2024 | $218.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-98.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield ENGN
| FY Oct 2025 | -27.3% |
| FY Oct 2024 | -12.6% |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | -86.7% |
| Apr 2026 | -22.9% |
| Jan 2026 | -16.3% |
| Oct 2025 | -27.3% |
| Jul 2025 | -49.1% |
| Apr 2025 | -36.0% |
| Jan 2025 | -19.7% |
| Oct 2024 | -12.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing ENGN
| FY Oct 2025 | 0.02x |
| FY Oct 2024 | n/a |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | 0.01x |
| Jan 2026 | 0.03x |
| Oct 2025 | 0.02x |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | n/a |
| Oct 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-10 | 2024-10 | 2023-10 | 2022-10 | |
|---|---|---|---|---|
| Operating income | -$123.2M | -$62.3M | -$26.1M | -$19.4M |
| Net income | -$117.3M | -$55.1M | -$99.9M | -$24.5M |
| EPS (diluted) | 2.29 | 1.46 | 151.22 | 44.30 |
| Operating cash flow | -$99.2M | -$48.3M | -$24.7M | -$17.6M |
| Cash | $50.2M | $173.0M | $81.5M | $20.4M |
| Long-term debt | n/a | $0 | $0 | $17.4M |
| Dividends paid | n/a | n/a | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
ENGN Stock Sonar score 5/7 axes
Find similar shapesCompareENGN ranks highest on financial health (99th percentile) and risk and compliance (62nd), and lowest on institutional and government (43rd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ENGN filings, in plain words
Are enGene Therapeutics insiders buying or selling ENGN?
In the 180 days to 2026-10-28, enGene Therapeutics insiders were net buyers, a net $10.1K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, enGene Therapeutics insiders were net buyers of ENGN, a net $10.1K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
